<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Clin Invest</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Clin. Invest</journal-id>
<journal-id journal-id-type="publisher-id">J Clin Invest</journal-id>
<journal-title-group>
<journal-title>The Journal of Clinical Investigation</journal-title>
</journal-title-group>
<issn pub-type="ppub">0021-9738</issn>
<issn pub-type="epub">1558-8238</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31305265</article-id>
<article-id pub-id-type="pmc">6668676</article-id>
<article-id pub-id-type="publisher-id">128521</article-id>
<article-id pub-id-type="doi">10.1172/JCI128521</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The gut-bone axis: how bacterial metabolites bridge the distance</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zaiss</surname>
<given-names>Mario M.</given-names>
</name>
<email>mario.zaiss@uk-erlangen.de</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jones</surname>
<given-names>Rheinallt M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schett</surname>
<given-names>Georg</given-names>
</name>
<email>georg.schett@uk-erlangen.de</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Pacifici</surname>
<given-names>Roberto</given-names>
</name>
<email>roberto.pacifici@emory.edu</email>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany.</aff>
<aff id="A2"><label>2</label>Department of Pediatrics and</aff>
<aff id="A3"><label>3</label>Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University, Atlanta, Georgia, USA.</aff>
<aff id="A4"><label>4</label>Immunology and Molecular Pathogenesis Program, Emory University, Atlanta, Georgia, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Roberto Pacifici, Division of Endocrinology, Metabolism and Lipids, Emory University School of Medicine, 101 Woodruff Circle, Room 1309, Atlanta, Georgia 30322, USA. Phone: 404.712.8420; Email: <email>roberto.pacifici@emory.edu</email>.</corresp>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> RP was the principal investigator in a research grant from VSL Pharmaceuticals.</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2019-07-15T16:00:00-0400" publication-format="electronic">
<day>15</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2019-07-15T16:00:00-0400" publication-format="electronic">
<day>15</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date date-type="pub" iso-8601-date="2019-08-01T16:00:00-0400" publication-format="print">
<day>1</day>
<month>8</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>8</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>129</volume>
<issue>8</issue>
<fpage>3018</fpage>
<lpage>3028</lpage>
<permissions>
<copyright-statement>© 2019 American Society for Clinical Investigation</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://www.jci.org/articles/view/128521">This article is available online at https://www.jci.org/articles/view/128521</self-uri>
<abstract>
<p>The gut microbiome is a key regulator of bone health that affects postnatal skeletal development and skeletal involution. Alterations in microbiota composition and host responses to the microbiota contribute to pathological bone loss, while changes in microbiota composition that prevent, or reverse, bone loss may be achieved by nutritional supplements with prebiotics and probiotics. One mechanism whereby microbes influence organs of the body is through the production of metabolites that diffuse from the gut into the systemic circulation. Recently, short-chain fatty acids (SCFAs), which are generated by fermentation of complex carbohydrates, have emerged as key regulatory metabolites produced by the gut microbiota. This Review will focus on the effects of SCFAs on the musculoskeletal system and discuss the mechanisms whereby SCFAs regulate bone cells.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>